Jefferies raised the firm’s price target on Agilent (A) to $130 from $120 and keeps a Hold rating on the shares. Earlier this week, Agilent launched Altura Ultra Inert High-performance Liquid Chromatography columns, the company’s first significant column launch in a decade, which adds an attractive consumables product cycle to compliment the instrument side, the analyst tells investors in a research note. The firm expects a nice pricing benefit, with early checks showing +20% on like-for-like columns and success similar to Waters’ (WAT) MaxPeak column launch a few years ago could add a low single digit percentage bump to its liquid chromatography/mass spectrometry business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent price target raised to $145 from $125 at Barclays
- Agilent announces insight series alarm resolution systems for airport security
- Agilent’s Balanced Outlook: Hold Rating Amid Growth Prospects and Valuation Concerns
- Agilent price target raised to $130 from $128 at BofA
- Agilent pharmDx receives EU class C companion diagnostic certification